SCHEMBL18172652

SCHEMBL18172652

CC/C(=C\C(C)=C\c1ccccc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
TSHR P16473 1/20 0.52
AKR1C3 P42330 1/20 0.52
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
RECQL P46063 1/20 0.49
HTT P42858 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPC1 O15118 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
GLA P06280 1/20 0.43
TBXAS1 P24557 2/20 0.43
LMNA P02545 2/20 0.42
AKR1C1 Q04828 1/20 0.42
MTNR1A P48039 2/20 0.41
MTNR1B P49286 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8073194 1.00 ALDH1A1 (0.52) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9
SCHEMBL57683 0.83 CYP3A4 (0.63) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9
SCHEMBL309762 0.83 CYP3A4 (0.63) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9
SCHEMBL2918640 0.83 CYP3A4 (0.63) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9
SCHEMBL18183127 0.83 MEN1 (0.62) ALDH1A1TSHRAKR1C3CYP2C9RECQL
SCHEMBL5160749 0.81 CYP3A4 (0.45) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9
SCHEMBL5163102 0.81 AKR1C3 (0.54) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9
Methacrylic Acid SCHEMBL10714804 0.79 CYP3A4 (0.54) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9
SCHEMBL2810168 0.78 AKR1C3 (0.70) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9
SCHEMBL30752458 0.78 RECQL (0.70) ALDH1A1TSHRAKR1C3CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286172-B1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2019-06-12 EP disclosed
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2018-10-11 US disclosed
EP-3286172-A1 LSD1 INHIBITORS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2018-02-28 EP disclosed
WO-2016172496-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF KDM1B, KDM1A, KDM2A ALDH1A1 187/4885TSHR 4232/4885AKR1C3 2059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.